InMed shareholders face near-total dilution and should consider the high risk of deal failure or CVRs expiring worthless. Monitor the shareholder vote and Nasdaq listing condition; if the merger closes, the stock will effectively become a vehicle for Mentari's pipeline.
Drugs in focus
INM drug pipeline →MT-001
● Neutral Named in this S-4- Impact
- Phase
- Preclinical (IND-enabling)
- Time to market
- Unknown — still preclinical. If successful through Phases 1-3, a potential approval would be 5+ years away.
- Next catalyst
- None dated
What to watchMT-001 is too early for a binary trade, no human data exists yet and Phase 2a data is two+ years out. The real near-term story for INM is the reverse-merger close (expected by Dec 31, 2026) and whether the $290M PIPE fully funds through 2028 as promised. Post-merger the ticker changes, so current INM holders are effectively buying Mentari's preclinical pipeline at the merged entity's valuation. Watch for the IND/CTA filing mid-2026 as a first proof of life.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 6 $1.56entry
- T+1 · 4mo ago +3.21%α +2.33% · $1.61
- T+5 · 4mo ago +6.41%α +5.48% · $1.66
- T+20 · 4mo ago −3.85%α −3.43% · $1.50
- T+60 · 7w ago −12.82%α −16.39% · $1.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InMed Pharmaceuticals filed an S-4 registration statement for its merger with Mentari Therapeutics. The deal is structured as a reverse merger in which InMed shareholders will own only ~1.51% of the combined company, while Mentari securityholders (including investors in a $290M pre-closing financing) will own ~98.49%. InMed's legacy business will be wound down, and shareholders will receive contingent value rights (CVRs) with uncertain payoff. The merger is expected to close in Q3 2026, subject to shareholder and regulatory approvals.
Key Facts
- InMed shareholders will own approximately 1.51% of the combined company post-merger.
- Mentari securityholders (including $290M pre-closing financing investors) will own approximately 98.49%.
- InMed is winding down its only revenue-generating segment (BayMedica) and faces going-concern uncertainty.
- InMed shareholders will receive CVRs tied to disposition of legacy assets, which may be valueless.
- The merger is conditioned on Nasdaq listing approval for the combined company's stock under symbol MTRI.
- InMed board recommends voting for all proposals; if merger fails, InMed may liquidate.
Financial Impact
Massive dilution for InMed shareholders: ownership drops from 100% to ~1.51%. The $290M pre-closing financing values Mentari at a substantial premium to InMed's current market cap of $4M.
Risk Factors
- Merger may fail to close due to shareholder disapproval or Nasdaq listing issues.
- CVRs may never pay out if legacy assets are not monetized.
- Combined company will need substantial additional capital post-merger.
- InMed's stock may be delisted if Nasdaq conditions are not met.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4 Filing (Primary) | 0001193125-26-294455 |
| Document: d131177dex32.htm | 0001193125-26-294455 |
| Document: d131177dex1022.htm | 0001193125-26-294455 |
| Document: d131177dex420.htm | 0001193125-26-294455 |
Track record
22 reports on INM
5 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +24.51% at T+1 after the Nov 3, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $16.00 Now $19.87 +24.19% settles Dec 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $13.21 Now $19.87 +50.42% settles Dec 4
- Nov 3, 202613d ago 8-K Bearish 6/10 Entry $1.75 Now $19.87 −1035.43% settles Dec 3
- Nov 2, 202614d ago 425 Neutral 3/10 Entry $1.68 Now $19.87 +1082.74% settles Dec 2
- Oct 26, 202621d ago 425 Neutral 3/10 Entry $1.59 Now $19.87 +1149.69% settles Nov 24
- Oct 7, 20265w ago SC 13G/A Bullish 5/10 Entry $1.33 to $1.32 Now $19.87 +1393.99% ▼ −0.68% +4.61% vs SPY
- Oct 2, 20266w ago EFFECT Neutral 3/10 Entry $1.33 to $1.60 Now $19.87 +1393.99% ▲ +20.30% +22.11% vs SPY
- Sep 18, 20268w ago 8-K Bearish 6/10 Entry $1.38 to $1.37 Now $19.87 −1339.86% ▲ +1.06% +0.15% vs SPY
- Sep 9, 20269w ago 425 Neutral 6/10 Entry $1.31 to $1.33 Now $19.87 +1416.79% ▲ +1.53% −0.60% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers